title: Head and neck tumor cell radiation response occurs in the presence of IGF1.
abstract: Radiation therapy for head and neck cancer results in severe secondary side-effects in salivary glands. We previously demonstrated that the administration of IGF1 preserves or restores salivary gland function following radiation. Based on these findings, we propose to study the effect of IGF1 on human head and neck carcinoma cells. Head and neck tumor cells treated with radiation have significant reductions in tumor cell survival, as measured by MTT and crystal violet assays, regardless of IGF1 pre-treatment. Head and neck squamous carcinoma cell xenografts treated with concurrent radiation+IGF1 also exhibit significant tumor growth delay; however, growth rates are elevated compared with those in irradiated xenografts. In contrast, administration of IGF1 after radiation treatment has no effect on tumor xenograft growth rates. Analysis of these data suggests that localized delivery may be required for concurrent therapy to prevent secondary side-effects of radiotherapy, while post-therapy administration of IGF1 could be considered for the restoration of salivary function.
authors.affiliation: Department of Nutritional Sciences, University of Arizona, PO Box 210038, Tucson, AZ 85721, USA.
authors.forename: K
authors.initials: K
authors.lastname: Victory
authors.forename: R
authors.initials: R
authors.lastname: Burd
authors.forename: A
authors.initials: A
authors.lastname: Fribley
authors.forename: S
authors.initials: S
authors.lastname: Sittadjody
authors.forename: D
authors.initials: D
authors.lastname: Arnett
authors.forename: R R
authors.initials: RR
authors.lastname: Klein
authors.forename: K H
authors.initials: KH
authors.lastname: Limesand
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D016371:Cranial Irradiation / Q000009:adverse effects; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D016014:Linear Models; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011832:Radiation Injuries / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011867:Radioisotope Teletherapy; D017526:Receptor, IGF Type 1 / Q000528:radiation effects; D012469:Salivary Glands / Q000187:drug effects / Q000528:radiation effects*; D018709:Statistics, Nonparametric
chemical_list: D003037:Cobalt Radioisotopes; D011837:Radiation-Protective Agents; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1